Cytokinetics

Yahoo Finance • 13 days ago

Catalyst Watch: OPEC meeting, FedEx talks freight, inflation reads, and SpaceX IPO buzz

[Wall street and Broadway road sign in New York City] Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. SUN... Full story

Yahoo Finance • 24 days ago

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential

Sarissa Capital Management established a new position in Biohaven Ltd.(NYSE:BHVN) during the fourth quarter, acquiring 513,184 shares worth $5.79 million at quarter’s end, according to a February 17, 2026, SEC filing. What happened Accor... Full story

Yahoo Finance • 26 days ago

DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing

What happened According to an SEC filing dated February 17, 2026, DAFNA Capital Management LLC reduced its stake in iShares Biotechnology ETF(NASDAQ:IBB) by 34,405 shares during the fourth quarter of 2025. The fund’s quarter-end IBB posit... Full story

Yahoo Finance • last month

Assessing Cytokinetics (CYTK) Valuation After Recent Share Price Weakness And Aficamten Expectations

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Cytokinetics stock overview Cytokinetics (CYTK) has been drawing attention as investors reassess... Full story

Yahoo Finance • 2 months ago

Cytokinetics aims for over 50% new patient share for MYQORZO by end of 2026 as global commercial launch accelerates

Earnings Call Insights: Cytokinetics (CYTK) Q4 2025 MANAGEMENT VIEW * Robert I. Blum, CEO, stated that "the fourth quarter of 2025 marked a defining moment for Cytokinetics with the FDA approval of MYQORZO for the treatment of adults w... Full story

Yahoo Finance • 2 months ago

Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cytokinetics, Incorporated European Commission Approval Based on Results of SEQUOIA-HCM First European Launch Expected in Germany in Q2 2026 SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasd... Full story

Yahoo Finance • 2 months ago

Cytokinetics, Incorporated (CYTK): A Bull Case Theory

We came across a bullish thesis on Cytokinetics, Incorporated on Valueinvestorsclub.com by Bohr. In this article, we will summarize the bulls’ thesis on CYTK. Cytokinetics, Incorporated's share was trading at $65.16 as of February 2nd.Coge... Full story

Yahoo Finance • 4 months ago

Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Holley Inc. (NYSE: HLLY); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf

PHILADELPHIA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (NASDAQ: CYTK): Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. (NASDAQ: CYTK). The investigation concerns whether certain off... Full story

Yahoo Finance • 4 months ago

Is First U.S. MYQORZO Approval Reshaping The Investment Case For Cytokinetics (CYTK)?

Cytokinetics has now secured U.S. FDA approval for MYQORZO (aficamten) tablets for adults with symptomatic obstructive hypertrophic cardiomyopathy, following earlier regulatory progress in China and a positive opinion in Europe. This first... Full story

Yahoo Finance • 4 months ago

Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO

(RTTNews) - The biotech industry witnessed several key events this week, including major FDA approvals, acquisitions, pivotal clinical trial results and setbacks. • A series of FDA approvals were announced during the week, with GSK, Haloz... Full story

Yahoo Finance • 4 months ago

Cytokinetics gains FDA approval of aficamten for hypertrophic cardiomyopathy

[Fda Approved Stamp] atakan * The US FDA has granted approval to Cytokinetics' (CYTK [https://seekingalpha.com/symbol/CYTK]) Myqorzo (aficamten), its treatment for symptomatic obstructive hypertrophic cardiomyopathy. * The treatment w... Full story

Yahoo Finance • 4 months ago

Cytokinetics Wins FDA Approval For Its First Drug, Taking On Bristol Myers

Cytokinetics won its first Food and Drug Administration approval late Friday, leading shares to jump in after-hours action. Continue Reading... Full story

Yahoo Finance • 4 months ago

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company’s First FDA-Approved Medicine Company to Host Investor... Full story

Yahoo Finance • 4 months ago

This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock?

Key Points Cytokinetics is a late-stage biopharmaceutical company targeting muscle function. Its stock has gained almost 30% this year, besting the S&P 500. It recently celebrated a big win in China, but legal issues at home could threate... Full story

Yahoo Finance • 4 months ago

Why Cytokinetics CEO Is Optimistic As FDA Deadline On Aficamten Looms

Cytokinetics is on the cusp of its first FDA approval, analysts say, leading up to the agency's decision date for the drug called aficamten. Continue Reading... Full story

Yahoo Finance • 4 months ago

Stocks Settle Higher on Upbeat Tech Outlook and Cooling Inflation

The S&P 500 Index ($SPX) (SPY) on Thursday closed up by +0.79%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up by +0.14%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up by +1.51%.  December E-mini S&P futures (ESZ25) rose +0.74%... Full story

Yahoo Finance • 4 months ago

Stocks Rally as Chip Makers Soar and US Price Pressures Ease

The S&P 500 Index ($SPX) (SPY) today is up by +1.28%, the Dow Jones Industrials Index ($DOWI) (DIA) is up by +0.82%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up by +1.91%.  December E-mini S&P futures (ESZ25) are up +1.27%, and December E... Full story

Yahoo Finance • 4 months ago

Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf

PHILADELPHIA, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (NASDAQ: CYTK): Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. (NASDAQ: CYTK). The investigation concerns whether certain off... Full story

Yahoo Finance • 4 months ago

Notice For Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. (NYSE: MOH); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Investigating Claims on Your Behalf

PHILADELPHIA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (NASDAQ: CYTK): Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. (NASDAQ: CYTK). The investigation concerns whether certain off... Full story

Yahoo Finance • 4 months ago

Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf

PHILADELPHIA, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (NASDAQ: CYTK): Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. (NASDAQ: CYTK). The investigation concerns whether certain off... Full story